Sofinnova Partners
7-11 Bd HaussmannParis, 75009
Website: sofinnovapartners.com
Firm Size
- Assets Under Management (AUM):$1.6 Billion
- Number of Funds:15
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Sofinnova Partners is a venture capital firm with a strong presence in Paris, France. Established in 1972, the firm specializes in early-stage investments in the life sciences sector, focusing on biopharmaceuticals, medical devices, digital health, and industrial biotechnology. With a team of experienced investment professionals, Sofinnova Partners has successfully supported numerous entrepreneurs and companies in developing their innovations and bringing them to the market. Located in Paris, the firm benefits from the city's vibrant ecosystem and access to a network of industry experts and academic institutions. Sofinnova Partners actively engages with entrepreneurs, providing not only financial support but also strategic guidance and support throughout the growth of their ventures. The firm has a history of successful investments, including many breakthrough companies that have transformed the life sciences industry. With offices in Paris, London, and San Francisco, Sofinnova Partners is well-positioned to identify and invest in promising startups globally. In summary, Sofinnova Partners in Paris is a reputable venture capital firm specializing in early-stage investments in the life sciences sector. Through its expertise and strategic support, the firm aims to help entrepreneurs and startups thrive and make a significant impact in their respective fields.Latest News
Powered by
Mar 20, 2024: Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first-in-class treatments and transform cancer into a curable disease
Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, today announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel , and Olivier Pomel, CEO, and co-founder of Datadog.
Jan 05, 2024: GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer
GlycoEra AG, a pioneering company advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders, today announced the expansion of its Series A financing with an investment from Bristol Myers Squibb (BMS). BMS joins existing investors, including 5AM Ventures, Roche Venture Fund and Sofinnova Partners, to advance GlycoEra's preclinical programs. GlycoEra also announced the addition of industry veteran Greg Fralish , Ph.D., as Chief Business Officer to expand and strengthen its leadership team.
Jun 13, 2023: LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024
LSI, the company behind LSI Emerging Medtech Summits, the partnering events for global leaders building breakthrough healthcare businesses, today announced it will host its next USA Emerging Medtech Summit, LSI USA '24, on March 18 through 22 at the Monarch Beach Resort, Waldorf Astoria in Dana Point, California .